ArticleBMC gastroenterology2025
Visceral adiposity index as a predictor of metabolic dysfunction-associated steatotic liver disease: a cross-sectional study.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Association between visceral adiposity index and metabolic dysfunction-associated steatotic liver disease in adults with type 1 diabetes mellitus: an exploratory cross-sectional study.Journal of endocrinological investigation · 2026Article
- Applying Artificial Intelligence to Childhood Obesity: T2DM and MASLD Risk Predictive Models.Diagnostics (Basel, Switzerland) · 2026Review
- Cyclodipeptides Reversed Liver Damage and Adipose Tissue Dysfunction in a Chronic Obesity MASLD Rat Model by Remodeling White Adipocytes Toward a Beige-like Adipocyte Phenotype.Molecules (Basel, Switzerland) · 2026Article
- Unveiling sex-specific cardiometabolic and adiposity risk profiles for precision prevention.European journal of medical research · 2026Article
- Visceral adiposity as a key predictor of metabolic dysfunction-associated steatotic liver disease: an analytical cross-sectional study in a tertiary care hospital of Karachi, Pakistan.BMC medical imaging · 2026Article
- Determinants of metabolic dysfunction associated steatotic liver disease and liver fibrosis in patients with type 2 diabetes mellitus: a cross-sectional study.Frontiers in medicine · 2026Article
- Adiposity and Metabolic Indices in the Diagnosis and Histological Stage Association of Metabolic Dysfunction-Associated Steatotic Liver Disease.Journal of clinical medicine · 2025Article
- Mediterranean diet adherence and tirzepatide: real-world evidence on adiposity indices and insulin resistance beyond weight loss.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe association between visceral adiposity index (VAI) and metabolic dysfunction-associated steatotic liver disease (MASLD) remains unestablished. Our study sought to investigate the potential relationship between VAI and MASLD risk.
methodsThis study employed data from the 2017-2018 National Health and Nutrition Examination Survey (NHANES). Weighted multivariable regression models, subgroup analyses, and machine learning algorithms were used to evaluate associations and predictive performance.
resultsHigher VAI tertiles correlated with increased MASLD risk (adjusted OR for T3 vs. T1: 7.08, 95% CI: 4.35-11.5; P-trend=0.003). Machine learning models demonstrated robust predictive accuracy, with random forest (AUC=0.869) and gradient boosting machine (AUC=0.868) outperforming non-invasive scores. However, lipid accumulation product (LAP, AUC=0.834) and fatty liver index (FLI, AUC=0.833) achieved superior diagnostic performance compared to VAI (AUC=0.736), while maintaining clinical interpretability through simplicity and routine parameter availability.
conclusionsWhile VAI demonstrated significant positive associations with MASLD risk, non-invasive scores like LAP and FLI emerged as superior diagnostic tools, balancing accuracy with clinical practicality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.